HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

P&G/ADM

This article was originally published in The Tan Sheet

Executive Summary

Firms ally to form "Technology Council" to develop "innovative natural-based products" to be marketed by P&G or third parties. Archer Daniels Midland's nutritionals business includes NovaSoy, NutriSoy and Natural Source vitamin E; in November, ADM filed a GRAS notice with FDA for stanol esters in food (1"The Tan Sheet" Feb. 19, In Brief)

You may also be interested in...



ADM

Archer Daniels Midland and Lifeline Technologies enter licensing agreement for proprietary technologies expanding use of phytosterols and phytostanols to low-fat and non-fat foods, yogurts and beverages. Lifeline is a biotech firm focused on enhancing the health benefits of natural dietary components through novel formulation strategies. In November, ADM filed a GRAS notification with FDA for use of plant stanols as an ingredient in vegetable oil spreads, salad dressings, health drinks, health bars, yogurt-type products and as a raw material in the manufacture of plant sterol esters

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS132188

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel